5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | NEUTRAL | BUY | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 2.70▼ | 2.72▼ | 2.74▼ | 2.66▲ | 2.89▼ |
MA10 | 2.71▼ | 2.74▼ | 2.68▲ | 2.85▼ | 2.95▼ |
MA20 | 2.72▼ | 2.67▲ | 2.65▲ | 3.00▼ | 2.96▼ |
MA50 | 2.73▼ | 2.67▲ | 2.73▼ | 3.03▼ | 4.34▼ |
MA100 | 2.68▲ | 2.77▼ | 2.98▼ | 3.08▼ | 5.52▼ |
MA200 | 2.67▲ | 2.99▼ | 2.98▼ | 4.17▼ | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.002▼ | 0.003▲ | 0.020▲ | -0.057▼ | 0.071▲ |
RSI | 39.902▼ | 53.166▲ | 51.170▲ | 42.420▼ | 40.317▼ |
STOCH | 20.833 | 52.889 | 82.258▲ | 16.820▼ | 40.009 |
WILL %R | -75.000 | -40.000 | -36.364 | -75.229▼ | -70.690 |
CCI | -82.353 | -16.170 | 46.512 | -62.378 | -108.298▼ |
MA | $OBIO Price Crossed Above MA(7) | Set Alert |
Saturday, August 09, 2025 10:00 PM
NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) announced a major expansion to the patient eligibility criteria for its ongoing BACKBEAT study, aimed at evaluating the effectiveness of ...
|
Friday, August 08, 2025 08:59 AM
Orchestra BioMed (NASDAQ:OBIO) stock gains as the FDA-approved protocol update expands its pivotal BACKBEAT study for its AVIM therapy in hypertension. Read more here.
|
Friday, August 08, 2025 05:10 AM
Orchestra BioMed (Nasdaq:OBIO) announced today that it began the rollout of a protocol update for its BACKBEAT study.
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
08/08/25 | 2.63 | 2.78 | 2.62 | 2.71 | 795,896 |
07/08/25 | 2.68 | 2.68 | 2.55 | 2.60 | 429,746 |
06/08/25 | 2.69 | 2.7391 | 2.59 | 2.64 | 408,618 |
05/08/25 | 2.73 | 2.755 | 2.62 | 2.67 | 853,941 |
04/08/25 | 2.52 | 2.71 | 2.52 | 2.68 | 580,304 |
01/08/25 | 2.70 | 2.75 | 2.44 | 2.44 | 1,721,879 |
31/07/25 | 3.14 | 3.19 | 3.04 | 3.06 | 354,391 |
30/07/25 | 3.16 | 3.27 | 3.08 | 3.12 | 105,841 |
29/07/25 | 3.43 | 3.53 | 3.135 | 3.16 | 230,694 |
28/07/25 | 3.29 | 3.42 | 3.29 | 3.40 | 132,116 |
|
|
||||
|
|
||||
|
|